Wolwo Pharma(SZ:300357) Xin Lang Zheng Quan·2025-10-31 00:56Core Viewpoint - Iwubio is a leading enterprise in the field of allergic disease diagnosis and treatment in China, holding over 80% market share in the desensitization treatment market, with strong technical barriers and brand advantages [1] Group 1: Business Performance - For Q3 2025, Iwubio reported revenue of 853 million yuan, ranking 16th among 34 companies in the industry, with the industry leader Changchun High-tech generating 9.807 billion yuan [2] - The main revenue source is dust mite drops, contributing 455 million yuan, accounting for 94.17% of total revenue [2] - The net profit for the same period was 335 million yuan, ranking 9th in the industry, with the top performer Tonghua Dongbao at 1.188 billion yuan [2][6] Group 2: Financial Ratios - As of Q3 2025, Iwubio's debt-to-asset ratio was 5.60%, down from 8.58% year-on-year, significantly lower than the industry average of 26.88% [3] - The gross profit margin stood at 95.37%, slightly up from 95.26% year-on-year, also higher than the industry average of 70.17% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.22% to 32,400, while the average number of shares held per shareholder increased by 6.63% to 14,900 [5] Group 4: Future Outlook - Iwubio's revenue for the first three quarters of 2025 increased by 16.86% year-on-year, with net profit rising by 26.67% [6][7] - The company expects steady growth in core product revenues, with projections for net profits of 390 million yuan, 470 million yuan, and 570 million yuan for 2025 to 2027, corresponding to dynamic P/E ratios of 45, 37, and 30 [6] - The company is expanding its pipeline, with promising results from clinical trials for its yellow flower sublingual drops [7]